Delays in new drug applications in Japan and industrial RandD strategies

Clinical Pharmacology and Therapeutics

Volumn 87, Issue 2, 2010, Pages 212-218

  Hirai, Y ^a   Kinoshita, H ^a   Kusama, M ^a   Yasuda, K ^b   Sugiyama, Y ^a   Ono, S ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b Japan Pharmaceutical Manufacturers Association   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG;

ARTICLE; CLINICAL STUDY; CORRELATION ANALYSIS; DRUG APPROVAL; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG MARKETING; EUROPEAN UNION; JAPAN; LINEAR REGRESSION ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; UNITED STATES;

BIOLOGICAL PRODUCTS; CLINICAL TRIALS AS TOPIC; COMMERCE; COSTS AND COST ANALYSIS; DRUG APPROVAL; DRUG DESIGN; DRUG INDUSTRY; EUROPEAN UNION; GUIDELINES AS TOPIC; HUMANS; INTERNATIONAL COOPERATION; INVESTIGATIONAL NEW DRUG APPLICATION; JAPAN; RESEARCH; TIME FACTORS; UNITED STATES;

EID: 75749100539     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.215     Document Type: Article

References (14)

1. Fukuhara, H. Period between world frst launch and country launch. Ofce of Pharmaceutical Research. Research Paper No. 31, May 2006 (in Japanese).
2. Tsuji, K. & Tsutani, K. access to 334 new chemical entities (NCEs) in the US, EU and Japan. Iryo to Shakai. 17, 243-258 (2007) (in Japanese).
3. Danzon, P.M., Wang, Y.R., & Wang, L. The impact of price regulation on the launch delay of new drugs-evidence from twenty-fve major markets in the 1990s. Health Econ. 14, 269-292 (2005).
4. Cohen, J., faden, L., & Predaris, S. Patient access to pharmaceuticals: an international comparison. Eur. J. Health Econ. 8, 253-266 (2007).
5. Uchida, E. History of the discussion on ethnic diference at ICH. Yakugaku Zasshi 129, 213-221 (2009) (in Japanese).
6. Ministry of Education, Culture, Sports, Science and Technology, Ministry of Health, Labor and Welfare, & Ministry of Economy, Trade and Industry. five-year Strategy for Creation of Innovative Drugs and Medical Devices, april 2007, revised May 2008 and february 2009 (in Japanese).
7. Yasuda, K. & Ono, S. New drug development times in Japan. Time of clinical development and approval. Ofce of Pharmaceutical Research. Research Paper No. 42, September 2008 (in Japanese).
8. Ishibashi, K. Survey on "drug lag" in Japan. Ofce of Pharmaceutical Research. Research Paper No. 40, June 2008 (in Japanese).
9. Tsuji, K. & Tsutani, K. Drug lag of clinical importance. Jpn. J. Clin. Pharmacol. Ther. 39 (suppl.), S266 (2008) (in Japanese).
10. Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nature Rev. Drug Discov. 3, 711-715 (2004).
11. Kyle, M.K. The role of frm characteristics in pharmaceutical product launches. Rand J. Econ. 37, 602-618 (2006).
12. Ministry of Health and Welfare. Pharmaceutical and Food Safety Bureau Notifcation No.0928010 on Basic Concepts for Joint International Clinical Trials, September 2007.
13. Ministry of Health and Welfare. Pharmaceutical Afairs Bureau Notifcation No.739 and Pharmaceutical Review Division Notifcation No. 672 on Ethnic Factors in the Acceptability of Foreign Clinical Data, august 1998.
14. Kokusai Iyakuhin Joho. Pharmaceutical industry data and prospect. Kokusai Shogyo (in Japanese).